Today, Congress voted and passed its budget bill, which included a nearly indefinite renewal of the Zadroga Act, which provides heathcare for first responders and others impacted by events of 9/11, the results look promising. The Meso Foundation is hopeful that the bill will pass thus extending nearly indefinitely healthcare benefits to first responders who […]
This week, we announced the release of a search tool which will enable users on the Meso Foundation’s website to easily search through nearly 100 mesothelioma research projects the organization has funded since its inception.
“As we continue funding important research, it has become very important to create easy ways to sort through that research,” said […]
The Meso Foundation is pleased to announce that Tobias Peikert, MD, of Mayo Clinic, has taken on the role of its Science Advisory Board’s chair.
The Meso Foundation’s Science Advisory Board (SAB) is comprised of doctors and researchers who work within the mesothelioma field around the world. Members of the SAB are expected to review and score […]
On October 14, the SELLAS Life Sciences Group, a biotech company leading a Phase 2 study of the WT1 vaccine, released the study’s promising data. The Meso Foundation had funded part of the Phase 1 portion of this study, the results of which prompted the Department of Defense to also award it a large grant.
The company […]
Last week, at the World Conference on Lung Cancer, Dr. Raffit Hassan presented promising data on a novel agent, anetumab ravtansine, also known as BAY 94-9343. Anetumab ravtansine is an antibody-drug conjugate directed against the target molecule mesothelin which is highly expressed on mesotheliomas.
“Anetumab ravtansine shows encouraging efficacy in patients with advanced mesothelioma which warrants […]